TM Editors’ note: This article discusses a penny stock and/or microcap. Such stocks are easily manipulated; do your own careful due diligence.Company: Galapagos NVBloomberg ticker: GLPG NAMarket cap: US$2,722mBackground: Galapagos NV is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action, with a pipeline comprising Phase 3, 2, 1, pre-clinical and discovery studies in cystic fibrosis, inflammation, fibrosis, osteoarthritis, and other indications.
 World Class Benchmarking of Galapagos NV

  • Profitable Growth rank of 9 was same compared to the prior period’s 9th rank
  • This is poor performance compared to 410 medium Health Care companies worldwide.
  • Profitability rank of 9 was better than its Growth rank of 10
  • Profitability rank of 9 was the same compared to the prior period’s 9th rank
  • This is poor performance compared to peers
  • Growth rank of 10 was the same compared to the prior period’s 10th rank
  • This is poor performance compared to peers

    • More By This Author:Asian Stock: Hualan Biological Engineering
    Asian Stock: Run Long Construction
    US Stock: Oshkosh

    Print Friendly, PDF & Email

    Related Posts